Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0190-9622(97)70150-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review.
Arch Dermatol Res
January 2025
Department of Dermatology, College of Medicine, The Ohio State University Wexner Medical Center, 540 Officenter Place, Columbus, OH, 43230, USA.
The use of immunotherapy is an emerging treatment option for advanced malignancies. Cutaneous adverse events following cancer immunotherapy are well-documented in the literature. The rarer cutaneous adverse effects are less characterized, including eruptive keratoacanthomas (KA).
View Article and Find Full Text PDFConcurrent Eruptive Melanocytic Nevi and Multiple Keratoacanthomas Induced by Encorafenib.
Cureus
September 2024
Oncology, Biokliniki Athinon, Athens, GRC.
Article Synopsis
- - A case study discusses a 64-year-old male with metastatic colorectal cancer who developed severe itching and new skin lesions after treatment with encorafenib and panitumumab, medications targeting cancer pathways.
- - The patient showed a mix of skin lesions, including benign moles and keratoacanthomas, with further evaluation confirming a link between the skin reactions and the use of encorafenib, as validated by the Naranjo scale.
- - Stopping the medications led to significant improvement in skin lesions, highlighting the importance of ongoing skin assessments for patients on BRAF inhibitors to manage side effects effectively.
Delayed onset eruptive keratoacanthomas following immune checkpoint inhibitor therapy.
Int J Dermatol
September 2024
Department of Dermatology, The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Generalized Eruptive Keratoacanthoma (GEKA) after Pfizer mRNABNT162b2 (Comirnaty) COVID-19 Vaccination Successfully Treated with Cemiplimab.
Viruses
August 2024
Dermatology Unit "Daniele Innocenzi", "A. Fiorini" Hospital, via Firenze, 1, 04019 Terracina, Italy.
Article Synopsis
- * A 64-year-old man with a history of hypertension and diabetes developed multiple keratoacanthomas two weeks after his second booster dose, prompting diagnosis through physical and histopathological examinations.
- * The patient's condition improved significantly with treatment using cemiplimab, suggesting a possible immune-mediated reaction from the vaccine, but further studies are necessary to assess treatment safety and effectiveness.
Diffuse eruptive squamous atypia, also known as eruptive keratoacanthoma: Unique case presentation.
JAAD Case Rep
July 2024
Department of Dermatology, University of Wisconsin, Madison, Wisconsin.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!